When does Vertex report earnings?
Vertex Pharmaceuticals Incorporated · end-of-day data as of Nov 13, 2026
- PT$574.33 +6.6%
- ConsensusBuy · 33
- Trendbullish
- MAs4 of 4
- MA20×50Golden 5d ago
- Sector▲ +15.9%
- Earnings in90d
- P/E34.7x
- RSI53
- Support-1.2%
- Resistance+3.3%
- Off 52w high-5.3%
- Volume0.5x
- Bollingerupper half
- News1.00
- FCF yield+2.3%
- P/E vs sector+7.6%
- 52w range$412–$569
- ATR+2.9%
- Off ATH-5.3%
- P/E vs own+16.9%
- Insiders-$6.31M
- MACD-0.14
Updates with the 15-min delayed price. Not a forecast or investment advice.
![]()
The stock around its reports
Last close $538.60 · +7.4% over 2y · E earnings · D dividend · S split · A analyst rating change
Quarterly results
Q3 FY2026: Revenue +11.8% year over year, free cash flow 15.9% of revenue, operating margin 20.7%.
| Q3 FY2026 | Sep 30, 2026 | $3.44B | 2.56 | $546M | 84.7% | 20.7% | 19.0% |
| Q2 FY2026 | Jun 30, 2026 | $3.33B | 4.31 | $1.01B | 85.3% | 37.4% | 33.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.99B | 4.02 | $1.29B | 86.8% | 38.1% | 34.5% |
| Q4 FY2025 | Dec 31, 2025 | $3.23B | 4.65 | $349M | 85.6% | 40.3% | 36.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.08B | 4.20 | $1.14B | 86.5% | 38.6% | 35.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.96B | 3.99 | $927M | 86.3% | 38.8% | 34.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.77B | 2.49 | $778M | 86.9% | 22.7% | 23.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.91B | 3.50 | $492M | 85.5% | 35.2% | 31.4% |